Areterna's Messengers
The Next Era of RNA Therapeutics: Innovations, Challenges, and Opportunities in 2025
As we step into 2025, we have entered the next era of RNA therapeutics. The global biotech and pharmaceutical industries are increasingly integrating mRNA-based medicines and the undeniable potential of RNA into their discovery and development pipelines. While the...
Capped and Uncapped Reference Standards for mRNA Capping – Now Available
Stay ahead in mRNA research and development with our newly available capped and uncapped reference standards! A linear mRNA molecule primarily consists of five components: the 5' cap structure (5' Cap), the 5' untranslated region (5' UTR), the open reading frame...
The Multifaceted Role of Modified NTPs in mRNA Synthesis
Introduction Modified nucleoside triphosphates (NTPs) are the master keys that unlock the therapeutic potential of mRNA. By strategically incorporating these chemically modified building blocks during mRNA synthesis, researchers can enhance stability, translation...
Unlocking the Future of RNA: The Power of Self-Amplifying RNA (saRNA)
Introduction The development of mRNA vaccines to fight COVID-19 marked a transformative leap in medicine, showcasing the power of RNA technology to tackle infectious diseases. Despite its groundbreaking success, mRNA has some limitations—such as instability, the need...
mRNA Therapeutics: Overcoming Delivery Challenges with Nanoparticle Delivery Systems
mRNA therapeutics have emerged as a revolutionary force in medicine, riding the wave of success initially generated by mRNA vaccines for COVID-19. However, as the field progresses from vaccines to protein replacement therapies and beyond, it faces distinct hurdles,...
GMP Raw Materials Used in Clinical Trials
Synthgene Biotechnology, Areterna's parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial role in...
Why Animal-Origin-Free Raw Materials Are Crucial for mRNA Therapeutics
In the intricate realm of mRNA therapeutics manufacturing, the meticulous selection of raw materials plays a pivotal role in ensuring the safety, efficacy, and ethical integrity of the final product. One crucial consideration in this process is the sourcing of animal...
mRNA-LNP Encapsulation Service
To ensure effective in vivo delivery, mRNA vaccines rely on not only optimized antigen sequences but also a robust delivery system capable of overcoming extracellular barriers, facilitating endosomal escape, and evading intracellular immune responses. Lipid...
Fluc-eGFP mRNA, Dual-Reporter for Protein Expression
In recent years, mRNA vaccines and drugs have received widespread attention around the world. Areterna LLC is proud to introduce Fluc-eGFP mRNA (Catalog number: 11013-CAP), a cutting-edge tool to accelerate your mRNA research. This mRNA encodes both eGFP and...
dsRNA: an unwanted byproduct from mRNA IVT
In vitro transcription (IVT) remains the predominant method for large-scale mRNA synthesis due to its efficiency and scalability. However, a significant challenge associated with IVT is the residual double-stranded RNA (dsRNA) produced as a by-product. This dsRNA can...